Junta Gral Jun2025

Jun 23, 2025 | Investors

CONVOCATORIA DE JUNTA GENERAL ORDINARIA DE LA SOCIEDAD CANCERAPPY, S.L.

El órgano de administración de la sociedad Cancerappy, S.L. (en adelante, la “Sociedad”), de conformidad con la normativa legal y estatutaria en vigor, en fecha 26 de mayo de 2025, ha acordado convocar a los señores socios de esta Sociedad a la Junta General Ordinaria de socios, que tendrá lugar en la sede social de la Sociedad el próximo 26 de junio a las 19:00 horas, al objeto de deliberar y resolver acerca de los puntos comprendidos en el siguiente,

The board of the company Cancerappy, S.L. (hereinafter, the “Company”), in accordance with the legal and statutory regulations in force, on May 26th, 2024, has agreed to summon the partners of this Company to the Ordinary General Shareholders’ Meeting, which will take place at the Company’s headquarters next June 26th at 7:00 p.m., in order to deliberate and decide on the points included in the following,

China health innovation ecosystem

China health innovation ecosystem

May 28, 2024 | Artificial Intelligence, Investors

A Cancerappy delegation has participated in a roadshow of European companies to learn about the innovative health ecosystem in the Shanghai and Wuxi area.

Our CEO has had the opportunity to hold various meetings with different agents of the innovation ecosystem, especially in the health sector, including investors, local government officials, leaders of research and innovation centers, as well as biotech companies and laboratories.

We have been able to observe first-hand how China has evolved to reach a peak of technological innovation in the health sector that is enviable and leading in the world.

From all these meetings, we have achieved several collaboration agreements that represent the beginning of a great business adventure that Cancerappy is going to begin imminently.

Anglonordic

Anglonordic

May 5, 2022 | Entrepreneur, Investors, Oncology

ANGLONORDIC_CANCERAPPY

CancerAppy was present at Anglonordic 2022. An event in which we had the opportunity to contact investors and companies in the biotechnology sector and present our research projects.